India:

· India revenues at Rs 1,632 crores were up by 13% led by outperformance in focus therapies.

· As per AIOCD secondary market data, IPM growth for the quarter was 8%.

· Torrent’s chronic business grew at 14% vs IPM growth of 9%, driven by strong revival in cardiac divisions and continued traction in anti-diabetes (OAD) new launches.

· On a MAT basis Torrent has outperformed the market across focused therapies aided by strong new launch performance. Torrent has 21 brands in the Top 500 brands in IPM, with 13 brands more than 100 crores.

· For H1 FY25, revenues were Rs 3,267 crores, up by 14%.

Brazil:

· Brazil revenues at Rs 263 crores, were up by 4%.

· Constant currency revenues at R$ 174 million, were up by 17%.

· As per IQVIA QTD Aug 24, Torrent growth at 8% vs market growth of 8%.

· Growth was aided by performance of top brands, new launches and growth in generic segment.

· Torrent has currently twenty one products under ANVISA review.

· For H1 FY25, revenues were Rs 459 crores, up by 4% (Constant currency revenue: R$ 297 million, up by 13%).

Germany:

· Germany revenues at Rs 288 crores, were up by 8%.

· Constant currency revenues at Euro 31 million, were up by 6%.

· Growth momentum continues with incremental tender wins since last five quarters.

· For H1 FY25, revenues were Rs 572 crores, up by 9% (Constant currency revenue: Euro 63 million, up by 8%).

United States:

· US business revenues at Rs 268 crores, were up by 8%.

· Constant currency revenues at $32 million, were up by 7% compared to same period in the previous year. Sequential quarter sales were at a similar level.

· For H1 FY25, revenues were Rs 527 crores, down by 3% (Constant currency revenue: $63 million down by 4%). Adjusted for one off income in H1 23-24, constant currency de growth at 2%.